Liposomes targeting tumour stromal cells

References

• Akalu A, Cretu A, Brooks PC. 2005. Targeting integrins for the control of tumour angiogenesis. Expert Opin Investig Drugs 14:1475–1486.
   PubMed Web of Science ®Google Scholar
• Ali G, Boldrini L, Lucchi M, Mussi A, Corsi V, Fontanini G. 2009. Tryptase mast cells in malignant pleural mesothelioma as an independent favorable prognostic factor. J Thorac Oncol 4:348–354.
   PubMedGoogle Scholar
• Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C, Rio MC. 2005. Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Research 65:10862–10871.
   PubMed Web of Science ®Google Scholar
• Andreu P, Johansson M, Affara NI, Pucci F, Tan T, Junankar S, Korets L, Lam J, Tawfik D, Denardo DG, Naldini L, De Visser KE, De Palma M, Coussens LM. 2010. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17:121–134.
   Google Scholar
• Balint K, Conejo-Garcia JR, Buckanovich R, Coukos G 2008. Role of vascular leukocytes in ovarian cancer neovascularization. Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Radiation Injury 4:622, 273–280.
   Google Scholar
• Balkwill F, Charles KA, Mantovani A. 2005. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7:211–217.
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. 2010. Cancer and inflammation: Implications for pharmacology and therapeutics. Clin Pharmacol Ther 87:401–406.
   PubMed Web of Science ®Google Scholar
• Baluk P, Hashizume H, McDonald DM. 2005. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 15:102–111.
   PubMed Web of Science ®Google Scholar
• Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. 2003. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 163:1801–1815.
   PubMed Web of Science ®Google Scholar
• Banciu M, Fens MH, Storm G, Schiffelers RM. 2008. Antitumor activity and tumor localization of liposomal glucocorticoids in B16 melanoma-bearing mice. J Control Release 127:131–136.
   PubMed Web of Science ®Google Scholar
• Banciu M, Schiffelers RM, Fens MH, Metselaar JM, Storm G. 2006. Anti-angiogenic effects of liposomal prednisolone phosphate on B16 melanoma in mice. J Control Release 113:1–8.
   PubMed Web of Science ®Google Scholar
• Baum P, Muller D, Ruger R, Kontermann RE. 2007. Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells. J Drug Target 15:399–406.
   PubMed Web of Science ®Google Scholar
• Beyer M, Schultze JL. 2009. Regulatory T cells: Major players in the tumor microenvironment. Curr Pharm Des 15:1879–1892.
   PubMed Web of Science ®Google Scholar
• Bluth MJ, Zaba LC, Moussai D, Suarez-Farinas M, Kaporis H, Fan L, Pierson KC, White TR, Pitts-Kiefer A, Fuentes-Duculan J, Guttman-Yassky E, Krueger JG, Lowes MA, Carucci JA. 2009. Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation. J Investigat Dermatol 129:2451–2462.
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Lee J, Pruitt S, Nair S. 2009. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 16:900–911.
   PubMed Web of Science ®Google Scholar
• Brú A, Souto JC, Alcolea S, Antón R, Remacha A, Camacho M, Soler M, Brú I, Porres A, Vila L. 2010. Tumour cell lines HT-29 and FaDu produce proinflammatory cytokines and activate neutrophils in vitro: possible applications for neutrophil-based antitumour treatment. Mediators Inflamm. 817498.
   Google Scholar
• Bussolati B, Grange C, Sapino A, Camussi G. 2009. Endothelial cell differentiation of human breast tumour stem/progenitor cells. J Cellular Molec Med 13:309–319.
   PubMed Web of Science ®Google Scholar
• Caruso RA, Bersiga A, Rigoli L, Inferrera C. 2002. Eosinophil-tumor cell interaction in advanced gastric carcinoma: An electron microscopic approach. Anticancer Res 22:3833–3836.
   PubMedGoogle Scholar
• Celis JE, Moreira JM, Cabezon T, Gromov P, Friis E, Rank F, Gromova I. 2005. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: Toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Molec Cellular Proteomics 4:492–522.
   PubMed Web of Science ®Google Scholar
• Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. 2008. The Janus face of dendritic cells in cancer. Oncogene 27:5920–5931.
   Google Scholar
• Cinel L, Aban M, Basturk M, Ertunc D, Arpaci R, Dilek S, Camdeviren H. 2009. The association of mast cell density with myometrial invasion in endometrial carcinoma: A preliminary report. Pathol Res Pract 205:255–258.
   PubMedGoogle Scholar
• Crivellato E, Nico B, Ribatti D. 2008. Mast cells and tumour angiogenesis: New insight from experimental carcinogenesis. Cancer Lett 269:1–6.
   PubMed Web of Science ®Google Scholar
• Danhier F, Vroman B, Lecouturier N, Crokart N, Pourcelle V, Freichels H, Jerome C, Marchand-Brynaert J, Feron O, Preat V. 2009. Targeting of tumor endothelium by RGD-grafted PLGA-nanoparticles loaded with Paclitaxel. J Control Release 140:166–173.
   PubMed Web of Science ®Google Scholar
• de Visser KE, Korets LV, Coussens LM. 2005. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 7:411–423.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Druker BJ. 2003. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 55:401–423.
   PubMed Web of Science ®Google Scholar
• Della Rovere F, Granata A, Familiari D, D'arrigo G, Mondello B, Basile G. 2007. Mast cells in invasive ductal breast cancer: Different behavior in high and minimum hormone-receptive cancers. Anticancer Res 27:2465–2471.
   PubMed Web of Science ®Google Scholar
• Detoraki A, Staiano RI, Granata F, Giannattasio G, Prevete N, De Paulis A, Ribatti D, Genovese A, Triggiani M, Marone G. 2009. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J Allergy Clin Immunol 123:1142–1149, 1149 e1–5.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol 3:991–998.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. 2004. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148.
   PubMed Web of Science ®Google Scholar
• Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM. 2008. Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma. Br J Cancer 99:1256–1264.
   PubMed Web of Science ®Google Scholar
• Fogal V, Sugahara KN, Ruoslahti E, Christian S. 2009. Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis 12:91–100.
   Google Scholar
• Freitas I, Baronzio GF. 1994. Neglected factors in cancer treatment: Cellular interactions and dynamic microenvironment in solid tumors. Anticancer Res 14:1097–1101.
   PubMedGoogle Scholar
• Furuya M, Nishiyama M, Kasuya Y, Kimura S, Ishikura H. 2005. Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 1:277–290.
   PubMedGoogle Scholar
• Furuya M, Yonemitsu Y. 2008. Cancer neovascularization and proinflammatory microenvironments. Curr Cancer Drug Targets 8:253–265.
   PubMedGoogle Scholar
• Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal Doxorubicin: Review of animal and human studies. Clin Pharmacokinet 42:419–436.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. 2001. Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest 19:424–436.
   PubMed Web of Science ®Google Scholar
• Gabizon AA, Shmeeda H, Zalipsky S. 2006. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res 16:175–183.
   PubMed Web of Science ®Google Scholar
• Gano JB, Kleinerman ES. 1995. Liposomal MTP-PE: A promising new biologic response modifier. Oncol Nurs Forum 22:809–816.
   PubMedGoogle Scholar
• Ganss R. 2006. Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. J Cellular Molec Med 10:857–865.
   PubMed Web of Science ®Google Scholar
• Gazzaniga S, Bravo AI, Guglielmotti A, Van Rooijen N, Maschi F, Vecchi A, Mantovani A, Mordoh J, Wainstok R. 2007. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol 127:2031–2041.
   PubMed Web of Science ®Google Scholar
• Gosk S, Moos T, Gottstein C, Bendas G. 2008. VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 1778:854–863.
   PubMed Web of Science ®Google Scholar
• Gouranton E, El Yazidi C, Cardinault N, Amiot MJ, Borel P, Landrier JF. 2008. Purified low-density lipoprotein and bovine serum albumin efficiency to internalise lycopene into adipocytes. Food and Chemical Toxicology 46:3832–3836.
   PubMedGoogle Scholar
• Grivennikov SI, Greten FR, Karin M. 2010. Immunity, inflammation, and cancer. Cell 140:883–899.
   PubMed Web of Science ®Google Scholar
• Groot Kormelink T, Abudukelimu A, Redegeld FA. 2009. Mast cells as target in cancer therapy. Curr Pharm Des 15:1868–1878.
   PubMedGoogle Scholar
• Hamzah J, Altin JG, Herringson T, Parish CR, Hammerling GJ, O'Donoghue H, Ganss R. 2009. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol 183:1091–1098.
   PubMed Web of Science ®Google Scholar
• Hedstrom G, Berglund M, Molin D, Fischer M, Nilsson G, Thunberg U, Book M, Sundstrom C, Rosenquist R, Roos G, Erlanson M, Amini RM, Enblad G. 2007. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 138:68–71.
   PubMed Web of Science ®Google Scholar
• Hellberg C, Ostman A, Heldin CH. 2010. PDGF and vessel maturation. Recent Results Cancer Res 180:103–114.
   PubMedGoogle Scholar
• Hilgenbrink AR, Low PS. 2005. Folate receptor-mediated drug targeting: From therapeutics to diagnostics. J Pharm Sci 94:2135–2146.
   PubMed Web of Science ®Google Scholar
• Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK. 1998. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. Proc Natl Acad Sci USA 95:4607–4612.
   PubMed Web of Science ®Google Scholar
• Hu H, Ran YL, Zhang YS, Zhou Z, Harris SJ, Yu L, Sun LX, Pan J, Liu J, Lou JN, Yang ZH. 2009. Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target. Molec Cellular Proteomics 8:816–826.
   PubMed Web of Science ®Google Scholar
• Ikehara Y, Kojima N. 2007. Development of a novel oligomannose-coated liposome-based anticancer drug-delivery system for intraperitoneal cancer. Curr Opin Mol Ther 9:53–61.
   PubMed Web of Science ®Google Scholar
• Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE. 2003. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 22:6408–6423.
   PubMed Web of Science ®Google Scholar
• Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, Lee H, Temple K, Graves R, Pollard J, Chopra N, Russell RG, Sasisekharan R, Trock BJ, Lippman M, Calvert VS, Petricoin EF 3rd, Liotta L, Dadachova E, Pestell RG, Lisanti MP, Bonaldo P, Scherer PE. 2005. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Investigat 115:1163–1176.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, O'Brien S, Giles F, Kantarjian H. 2007. New targeted therapies for chronic myelogenous leukemia: Opportunities to overcome imatinib resistance. Semin Hematol 44:S25–31.
   PubMed Web of Science ®Google Scholar
• Janssen AP, Schiffelers RM, Ten Hagen TL, Koning GA, Schraa AJ, Kok RJ, Storm G, Molema G. 2003. Peptide-targeted PEG-liposomes in anti-angiogenic therapy. Int J Pharm 254:55–58.
   PubMed Web of Science ®Google Scholar
• Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. 2003. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4:393–403.
   PubMed Web of Science ®Google Scholar
• Ju MJ, Qiu SJ, Gao Q, Fan J, Cai MY, Li YW, Tang ZY. 2009. Combination of peritumoral mast cells and T-regulatory cells predicts prognosis of hepatocellular carcinoma. Cancer Sci 100:1267–1274.
   PubMedGoogle Scholar
• Kaminski A, Hahne JC, Haddouti EM, Florin A, Wellmann A, Wernert N. 2006. Tumour-stroma interactions between metastatic prostate cancer cells and fibroblasts. Int J Molec Med 18:941–950.
   PubMed Web of Science ®Google Scholar
• Keibel A, Singh V, Sharma MC. 2009. Inflammation, microenvironment, and the immune system in cancer progression. Curr Pharm Des 15:1949–1955.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Aulakh KS, Nair RE, Jones SA, Alard P, Kosiewicz MM, Egilmez NK. 2006. Reversing tumor immune suppression with intratumoral IL-12: Activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8(+) T effectors. J Immunol 177:6962–6973.
   PubMed Web of Science ®Google Scholar
• Kilinc MO, Gu T, Harden JL, Virtuoso LP, Egilmez NK. 2009. Central role of tumor-associated CD8+ T effector/memory cells in restoring systemic antitumor immunity. J Immunol 182:4217–4225.
   PubMed Web of Science ®Google Scholar
• Kim YI, Yu ES, Lee KW, Park EU, Song HG. 1987. Dedifferentiated liposarcoma of the liver. Cancer 60:2785–2790.
   PubMed Web of Science ®Google Scholar
• Kimura YN, Watari K, Fotovati A, Hosoi F, Yasumoto K, Izumi H, Kohno K, Umezawa K, Iguchi H, Shirouzu K, Takamori S, Kuwano M, Ono M. 2007. Inflammatory stimuli from macrophages and cancer cells synergistically promote tumor growth and angiogenesis. Cancer Sci 98:2009–2018.
   PubMed Web of Science ®Google Scholar
• Kinlen LJ. 1992. Malignancy in autoimmune diseases. J Autoimmun 5(Suppl. A):363–371.
   PubMedGoogle Scholar
• Knezevic V, Leethanakul C, Bichsel VE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin EF 3rd, Krizman DB. 2001. Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics 1:1271–1278.
   PubMed Web of Science ®Google Scholar
• Kuramoto Y, Kawakami S, Zhou S, Fukuda K, Yamashita F, Hashida M. 2008. Use of mannosylated cationic liposomes/immunostimulatory CpG DNA complex for effective inhibition of peritoneal dissemination in mice. J Gene Med 10:392–399.
   PubMed Web of Science ®Google Scholar
• Landen CN, Kim TJ, Lin YG, Merritt WM, Kamat AA, Han LY, Spannuth WA, Nick AM, Jennnings NB, Kinch MS, Tice D, Sood AK. 2008. Tumor-selective response to antibody-mediated targeting of alphavbeta3 integrin in ovarian cancer. Neoplasia 10:1259–1267.
   PubMed Web of Science ®Google Scholar
• Lang SA, Schachtschneider P, Moser C, Mori A, Hackl C, Gaumann A, Batt D, Schlitt HJ, Geissler EK, Stoeltzing O. 2008. Dual targeting of Raf and VEGF receptor 2 reduces growth and metastasis of pancreatic cancer through direct effects on tumor cells, endothelial cells, and pericytes. Molec Cancer Therapeut 7:3509–3518.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Aldrich M, Rollins L, Ren W, Goltsova T, Chen SY, Huang XF. 2009a. Attraction and activation of dendritic cells at the site of tumor elicits potent antitumor immunity. Molec Ther 17:1626–1636.
   PubMed Web of Science ®Google Scholar
• Lapteva N, Aldrich M, Weksberg D, Rollins L, Goltsova T, Chen SY, Huang XF. 2009b. Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity. J Immunother 32:145–156.
   PubMed Web of Science ®Google Scholar
• Le Bourhis X, Romon R, Hondermarck H. 2010. Role of endothelial progenitor cells in breast cancer angiogenesis: From fundamental research to clinical ramifications. Breast Cancer Res Treat 120:17–24.
   PubMedGoogle Scholar
• Legg JA, Herbert JMJ, Clissold P, Bicknell R. 2008. Slits and roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis 11:13–21.
   PubMed Web of Science ®Google Scholar
• Li J, Sausville EA, Klein PJ, Morgenstern D, Leamon CP, Messmann RA, Lorusso P. 2009. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-Vinca alkaloid conjugate EC145 in cancer patients. J Clin Pharmacol 49:1467–1476.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zhai B, Yang W, Yu LX, Dong W, He YQ, Chen L, Tang L, Lin Y, Huang DD, Wu HP, Wu MC, Yan HX, Wang HY. 2009. Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine. Molec Ther 17:2049–2057.
   PubMed Web of Science ®Google Scholar
• Loi M, Marchio S, Becherini P, Di Paolo D, Soster M, Curnis F, Brignole C, Pagnan G, Perri P, Caffa I, Longhi R, Nico B, Bussolino F, Gambini C, Ribatti D, Cilli M, Arap W, Pasqualini R, Allen TM, Corti A, Ponzoni M, Pastorino F. 2010. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma. J Control Release 145:66–73.
   Google Scholar
• Loomis K, Smith B, Feng Y, Garg H, Yavlovich A, Campbell-Massa R, Dimitrov DS, Blumenthal R, Xiao X, Puri A. 2010. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv. Exp Mol Pathol 88:238–249.
   PubMed Web of Science ®Google Scholar
• Lopez MV, Viale DL, Cafferata EG, Bravo AI, Carbone C, Gould D, Chernajovsky Y, Podhajcer OL. 2009. Tumor associated stromal cells play a critical role on the outcome of the oncolytic efficacy of conditionally replicative adenoviruses. PLoS One 4:e5119.
   Google Scholar
• Low PS, Kularatne SA. 2009. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 13:256–262.
   PubMed Web of Science ®Google Scholar
• Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. 2010. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther 9:176–182.
   Google Scholar
• Lu Y, Kawakami S, Yamashita F, Hashida M. 2007. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials 28:3255–3262.
   PubMed Web of Science ®Google Scholar
• Maeda H, Bharate GY, Daruwalla J. 2009. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharmaceut Biopharmaceut 71:409–419.
   PubMed Web of Science ®Google Scholar
• Meng Y, Beckett MA, Liang H, Mauceri HJ, Van Rooijen N, Cohen KS, Weichselbaum RR. 2010. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 70:1534–1543.
   PubMedGoogle Scholar
• Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. 2008. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 7:788–799.
   PubMed Web of Science ®Google Scholar
• Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Castonguay R, Monnell TE, Solban N, Ucran JA, Pearsall RS, Underwood KW, Seehra J, Kumar R. 2010. ALK1-Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 9:379–388.
   PubMed Web of Science ®Google Scholar
• Moore MM, Chua W, Charles KA, Clarke SJ. 2010. Inflammation and cancer: Causes and consequences. Clin Pharmacol Ther 87:504–508.
   PubMed Web of Science ®Google Scholar
• Mor G, Yue W, Santen RJ, Gutierrez L, Eliza M, Berstein LM, Harada N, Wang J, Lysiak J, Diano S, Naftolin F. 1998. Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67:403–411.
   PubMed Web of Science ®Google Scholar
• Nardin A, Lefebvre ML, Labroquere K, Faure O, Abastado JP. 2006. Liposomal muramyl tripeptide phosphatidylethanolamine: Targeting and activating macrophages for adjuvant treatment of osteosarcoma. Curr Cancer Drug Targets 6:123–133.
   PubMed Web of Science ®Google Scholar
• Ostman A, Augsten M. 2009. Cancer-associated fibroblasts and tumor growth – bystanders turning into key players. Curr Opin Genet Dev 19:67–73.
   PubMed Web of Science ®Google Scholar
• Park K. 2010. A new ligand for targeted drug delivery to tumor stromal cells. J Control Release 145:75.
   Google Scholar
• Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. 2001. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: Increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab 86:2281–2288.
   PubMed Web of Science ®Google Scholar
• Pluda JM, Parkinson DR. 1996. Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas. Cancer 78:680–687.
   PubMedGoogle Scholar
• Prakash J, De Jong E, Post E, Gouw AS, Beljaars L, Poelstra K. 2010. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 145:91–101.
   Google Scholar
• Roskelley CD, Bissell MJ. 2002. The dominance of the microenvironment in breast and ovarian cancer. Seminars Cancer Biol 12:97–104.
   PubMedGoogle Scholar
• Sadlonova A, Bowe DB, Novak Z, Mukherjee S, Duncan VE, Page GP, Frost AR. 2009. Identification of molecular distinctions between normal breast-associated fibroblasts and breast cancer-associated fibroblasts. Cancer Microenviron 2:9–21.
   PubMedGoogle Scholar
• Schiffelers RM, Koning GA, Ten Hagen TL, Fens MH, Schraa AJ, Janssen AP, Kok RJ, Molema G, Storm G. 2003. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J Control Release 91:115–122.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Storm G. 2008. Liposomal nanomedicines as anticancer therapeutics: Beyond targeting tumor cells. Int J Pharmaceut 364:258–264.
   PubMed Web of Science ®Google Scholar
• Schmid SA, Dietrich A, Schulte S, Gaumann A, Kunz-Schughart LA. 2009. Fibroblastic reaction and vascular maturation in human colon cancers. Int J Radiation Biol 85:1013–1025.
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results (SEER). 2006. SEER Cancer Statistics Review 1975–2006. Surveillance Research Program, NCI.
   Google Scholar
• Shain KH, Landowski TH, Dalton WS. 2000. The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance. Curr Opin Oncol 12:557–563.
   PubMed Web of Science ®Google Scholar
• Shen R, Ye Y, Chen L, Yan Q, Barsky SH, Gao JX. 2008. Precancerous stem cells can serve as tumor vasculogenic progenitors. Plos One 3:e1652.
   PubMedGoogle Scholar
• Sihto H, Tynninen O, Halonen M, Puputti M, Karjalainen-Lindsberg ML, Kukko H, Joensuu H. 2009. Tumour microvessel endothelial cell KIT and stem cell factor expression in human solid tumours. Histopathology 55:544–553.
   PubMedGoogle Scholar
• Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA. 2004. The fibroblast: Sentinel cell and local immune modulator in tumor tissue. Int J Cancer 108:173–180.
   PubMed Web of Science ®Google Scholar
• Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS, Smyth MJ, Parish CR. 2007. Regulation of carcinogenesis by IL-5 and CCL11: A potential role for eosinophils in tumor immune surveillance. J Immunol 178:4222–4229.
   PubMed Web of Science ®Google Scholar
• Stegmeier F, Warmuth M, Sellers WR, Dorsch M. 2010. Targeted cancer therapies in the twenty-first century: Lessons from imatinib. Clin Pharmacol Ther 87:543–552.
   Google Scholar
• Strouch MJ, Cheon EC, Salabat MR, Krantz SB, Gounaris E, Melstrom LG, Dangi-Garimella S, Wang E, Munshi HG, Khazaie K, Bentrem DJ. 2010. Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res 16:2257–2265.
   Google Scholar
• Tang DG, Conti CJ. 2004. Endothelial cell development, vasculogenesis, angiogenesis, and tumor neovascularization: An update. Semin Thromb Hemost 30:109–117.
   PubMed Web of Science ®Google Scholar
• Temming K, Schiffelers RM, Molema G, Kok RJ. 2005. RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Updat 8:381–402.
   PubMed Web of Science ®Google Scholar
• Tillmann T, Kamino K, Dasenbrock C, Germann PG, Kohler M, Morawietz G, Campo E, Cardesa A, Tomatis L, Mohr U. 1999. Ito cell tumor: Immunohistochemical investigations of a rare lesion in the liver of mice. Toxicol Pathol 27:364–369.
   PubMedGoogle Scholar
• Tokuda Y, Satoh Y, Fujiyama C, Toda S, Sugihara H, Masaki Z. 2003. Prostate cancer cell growth is modulated by adipocyte-cancer cell interaction. Bju Int 91:716–720.
   PubMedGoogle Scholar
• Turk MJ, Waters DJ, Low PS. 2004. Folate-conjugated liposomes preferentially target macrophages associated with ovarian carcinoma. Cancer Lett 213:165–172.
   PubMed Web of Science ®Google Scholar
• Vasiliev JM. 1964. The role of the changes on the microenvironment of epithelial and connective-tissue cells in the carcinogenesis. Acta Unio Int Contra Cancrum 20:1431–1432.
   PubMedGoogle Scholar
• Virchow R. 1863. Die Cellularpathologie in ihrer Begrundung auf physiologische und pathologische Gewebelehre. Berlin: August Hirschwald Verlag.
   Google Scholar
• Wong DTW, Bowen SM, Elovic A, Gallagher GT, Weller PF. 1999. Eosinophil ablation and tumor development. Oral Oncology 35:496–501.
   PubMedGoogle Scholar
• Xian XJ, Hakansson J, Stahlberg A, Lindblom P, Betsholtz C, Gerhardt H, Semb H. 2006. Pericytes limit tumor cell metastasis. J Clin Investigat 116:642–651.
   PubMed Web of Science ®Google Scholar
• Xing F, Saidou J, Watabe K. 2010. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Frontiers Biosci 15:166–179.
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, Zhang X, Zhang H, Nagai T, Zhang Q. 2005. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107:262–275.
   PubMed Web of Science ®Google Scholar
• Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. 2006. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. Br J Cancer 95:272–281.
   PubMed Web of Science ®Google Scholar
• Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. 2010. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: In vitro and in vivo studies. Eur J Pharm Biopharm 74:467–473.
   PubMed Web of Science ®Google Scholar
• Zhao H, Wang JC, Sun QS, Luo CL, Zhang Q. 2009. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer. J Drug Target 17:10–18.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Tesniere A, Kroemer G. 2006. Cancer despite immunosurveillance: Immunoselection and immunosubversion. Nat Rev Immunol 6:715–727.
   PubMed Web of Science ®Google Scholar